DrStore Healthcare Services, through its med-tech brand Tracky, has unveiled India’s first integrated real-time monitoring platform for GLP-1 therapies, aiming to revolutionize patient care and real-world evidence generation.
The platform consolidates glucose levels, body composition, activity, diet, and wearable data into a single dashboard, enabling continuous monitoring of patients undergoing GLP-1 treatment for diabetes and weight management.
By tracking multiple health streams in real time, Tracky empowers clinicians to optimize dosage, monitor side effects, and improve therapy adherence, while giving pharmaceutical companies a structured framework for large-scale real-world evidence collection.
“GLP therapies are transforming metabolic care, but their full impact depends on how well we can monitor and understand patient outcomes beyond the prescription,” said Neeraj Katare, Founder, Tracky. “We are building a continuous data layer that connects therapy with real-world patient insights enabling better decisions for clinicians and more meaningful evidence for pharmaceutical partners.”
GLP-1 therapies have surged in popularity globally and in India, but a critical gap persists: limited visibility into patient outcomes between clinic visits. Tracky’s platform addresses this by correlating glucose, weight, activity, and lifestyle data over time, providing clinicians a comprehensive view of patient progress and enabling evidence-based interventions.
“While GLP-1 therapies are driving strong clinical outcomes, there is still a gap when it comes to tracking patient progress in real-world settings. A platform that enables continuous monitoring and brings together multiple health parameters can help bridge this gap, offering better visibility into outcomes and enabling more proactive patient management,” said Dr Jothydev Kesavadev, Chairman at Jothydev's Diabetes and Research Center, Trivandrum, India.
“One of the biggest challenges with GLP therapies today is the lack of continuous visibility into how patients are responding outside the clinic. A platform that enables real-time monitoring of parameters like glucose, weight, and activity can significantly improve how we titrate treatment, manage side effects, and make more informed clinical decisions,” added Dr. Banshi Saboo, Chairman, International Diabetes Federation, South East Asia.
The platform also tackles long-term concerns around GLP-1 therapy outcomes, such as weight regain and metabolic relapse after treatment ends. By integrating lifestyle insights with continuous health monitoring, Tracky aims to make improvements more sustainable.
Several major pharmaceutical companies have already integrated Tracky’s platform into their GLP therapy programs to enhance patient adherence and outcome tracking.
